Ulinastatin Manufacturing: Viral Safety First

Urostatin is derived from human urine and inherently carries potential contamination risks from various viruses, including hepatitis B virus (HBV) and human immunodeficiency virus (HIV). As an intravenous medication primarily administered to critically ill patients with compromised immune systems, its use poses significant risks of severe cross-blood infections if the product contains live viruses. Furthermore, both domestic and international pharmacopoeias as well as Good Manufacturing Practice (GMP) standards impose mandatory requirements for viral control. Therefore, viral safety must be the paramount focus during production processes.